ライフサイエンスコーパス: PGD2

1 F(2alpha) (PGF2alpha), and prostaglandin D2 (PGD2).

2 ing abundant production of prostaglandin D2 (PGD2).

3 synthesis and secretion of prostaglandin D2 (PGD2).

4 s, leads to the release of prostaglandin D2 (PGD2).

5 ive with the native agonist prostaglandin D2(PGD2).

6 lls showed attenuated responses to exogenous PGD2.

7 all but statistically significant release of PGD2.

8 ggerated migratory response of cells against PGD2.

9 ed by nicotinic acid but not that induced by PGD2.

10 D2c-IsoP) would be predicted to rearrange to PGD2.

11 Mutation in CRE eliminated the response to PGD2.

12 bited CREB activation and c-fos induction by PGD2.

13 supply of arachidonic acid for metabolism to PGD2.

14 stidic localization of PGD1 and PGD3 but not PGD2.

15 l unit reacting to inflammation by producing PGD2.

16 s in the quartet1-2 background revealed that pgd2-1 pollen is vital and in vitro germination normal,

17 ailed analyses of the C-terminally truncated PGD2-1 protein showed that peroxisomal import and cataly

18 Reciprocal backcrosses of pgd2-1 suggested that missing PGD activity in peroxisome

19 ed vasodilation; the DP2-specific agonist DK-PGD2 (13,14-dihydro-15-keto-PGD2) did not induce cutaneo

20 d COX1/ALOX15/ALOX5/LTA4H(low) gene and PGE2/PGD2/15-HETE(high) and LXA4(low) eicosanoid profile.

21 The first total synthesis of 15(R)-Me-PGD2 3 is reported.

22 re compared by densitometry analysis between PGD2/3 and no-PGD participants.

23 Finally, lower LKB1 levels in PGD2/3 are associated with increased markers of EMT.

24 Within PGD2/3 participants, lower post-LTx LKB1 was associated

25 LKB1 was significantly downregulated in PGD2/3 sEVs compared with no-PGD sEVs.

26 matory responses associated with severe PGD (PGD2/3) can downregulate LKB1 levels in sEVs, predisposi

27 lts suggest that in post-LTx recipients with PGD2/3, downregulation of LKB1 protein levels in sEVs is

28 increase in the PFAS mixture associated with PGD2 (+34%, 95% CI: 8-66%), primarily driven by PFOS.

29 nd high-affinity uptake of PGE2, PGF2 alpha, PGD2, 8-iso-PGF2 alpha, and thromboxane B2.

30 produced by dehydration and isomerization of PGD2, a cyclooxygenase product.

31 Prostaglandin D2 (PGD2) acting at the CRTH2 receptor (chemoattractant rece

32 d to assess whether pesticides identified as PGD2-active could serve as ligands of the cyclooxygenase

33 These analyses showed that peroxisomal PGD2 activity is required for guided growth of the male

34 d and water and find that the binding of the PGD2 agonist leads to correlated rotations of helices of

35 PGD2 also increased Fos immunoreactivity in the basal le

36 Catalytic activity of L-PGDS produces PGD2, an endogenous somnogen.

37 CRTH2 internalized upon treatment with PGD2 and 11-dehydro TXB2 in eosinophils of controls.

38 stromal cell L-PGDS included high levels of PGD2 and 15-deoxy-delta(12,14)-PGD2 but low levels of 15

39 CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6, respectively.

40 During helminth infection or in organoids, PGD2 and CRTH2 down-regulated intestinal epithelial Il13

41 The combination of PGD2 and cysLTs (notably cysteinyl leukotriene E4 [LTE4]

42 icantly reduces antigen-induced secretion of PGD2 and cysteinyl-leukotriene.

43 etin (TSLP) acting on mast cells to generate PGD2 and facilitate tissue eosinophilia and nasal polypo

44 In this setting, PGD2 and its enantiomer generated by the IsoP pathway re

45 protein and bound to the endogenous agonist PGD2 and its selective derivative BW245C.

46 PGD2 and LTE4 activate TH2 cells through different pathw

47 PGD2 and LTE4 altered the transcription of a wide range

48 Combined inhibition of both PGD2 and LTE4 pathways might provide an effective therap

49 Blockade of PGD2 and LTE4 was tested by using TM30089, an antagonist

50 naling molecules by means of immunoblotting, PGD2 and macrophage inflammatory protein 1beta generatio

51 HF, and demonstrates a possible link between PGD2 and perturbed proliferation dynamics in epithelial

52 COX-2-derived PGD2 and PGE2 regulate Th9 cell differentiation by suppr

53 IL-17RB expression in vivo was inhibited by PGD2 and PGE2, which also reduced Th9 cell differentiati

54 Thus, combined treatment with PGD2 and RA substantially decreased tumor growth in huma

55 pounds identical in all respects to PGE2 and PGD2 and their respective enantiomers are generated in v

56 d by palmitic acid were mimicked by PGE2 and PGD2 and were reversed by cyclooxygenase inhibition or p

57 (LT)E4 , induced sputum fluid LTB4 , LTE4 , PGD2 , and PGE2 , plasma secretory phospholipase A2 (sPL

58 nations of plasmid vector that expresses gD (pgD2) and a recombinant modified vaccinia virus Ankara v

59 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs) are lipid medi

60 e enzyme (L-PGDS) that produces its agonist (PGD2) and in which this enzyme in turn acts as a cofacto

61 Also, levels of prostaglandin D2 (PGD2) and lipoxin A4 (LXA4) in patients with T1R were si

62 these human mast cells to secrete histamine, PGD2, and leukotriene C4 upon subsequent passive sensiti

63 d UFP-mediated increase in HETEs, HODEs, AA, PGD2, and LPA.

64 Similar polypeptide lengths of PGD1, PGD2, and PGD3 obscured which isoform may represent the

65 Other cycloxygenase products, PGE2, PGD2, and PGF2alpha, failed to activate p38 kinase in as

66 24, a DP1-selective antagonist, blocked both PGD2- and NA-induced vasodilation.

67 c acid for late, PGS2-dependent synthesis of PGD2; and (iv) a cytoplasmic PLA2-dependent step precede

68 ) and mast cell mediators (prostaglandin D2 [PGD2]) are critical activators of ILC2s.

69 These data identify PGD2 as a mediator of both the EPR and LPR in this model

70 Arachidonic acid (AA) and prostaglandin D2 (PGD2) as well as some of the lysophosphatidic acids (LPA

71 reening identified the GPCR ligands, S1P and PGD2, as factors that actively maintain the quiescent st

72 ulindac sulfide, and zomepirac displaced [3H]PGD2 binding at the mouse CRTH2 receptor (mCRTH2) with c

73 We find that PGD2 binds vertically to DP in the TM1237 region with th

74 ncomitantly induced PGHS-2 for delayed-phase PGD2 biosynthesis in activated BMMC.

75 igh levels of PGD2 and 15-deoxy-delta(12,14)-PGD2 but low levels of 15-deoxy-delta(12,14)-prostagland

76 elective CRTH2 agonist 13,14-dihydro-15-keto-PGD2 but not by the selective DP agonist BW245C, suggest

77 enzymatic rearrangement not only to PGE2 and PGD2, but also to levuglandins (LG) E2 and D2, which are

78 taxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in pati

79 mice overexpressing human PGD2 synthase, and PGD2 can enhance Th2 cytokine production in vitro from C

80 Dermal histamine and PGD2 contractions were measured using microdialysis.

81 These results indicate that PGD2 contributes to delayed antigen presentation and CD8

82 n peroxisomal import after dimerization, and PGD2 could be immunodetected in purified peroxisomes.

83 In addition to PGD2, CRTH2 can be activated by indomethacin, a nonselec

84 These data show that the PGD2-CRTH2 pathway negatively regulates the Type 2 cytok

85 revealed doubling in PFOA corresponding with PGD2 (cyclooxygenase pathway; +24.3%, 95% CI: 7.3-43.9%)

86 Exogenous application of PGD2 decreased WIHN in wild-type mice, and PGD2 receptor

87 r of skin regeneration, we hypothesized that PGD2 decreases follicle neogenesis.

88 cific agonist DK-PGD2 (13,14-dihydro-15-keto-PGD2) did not induce cutaneous vasodilation, and DP2-/-

89 amely, 24 h organ-cultured hHFs treated with PGD2 displayed reduced Ki-67 expression and EdU incorpor

90 (PG) receptors [EP2, EP4, prostacyclin (IP), PGD2 (DP)] and the four Gq/Gi-coupled receptors [EP1, EP

91 ceptors, shifting the role of the Langerhans/PGD2/DP1 pathway to that of an accomplice.

92 hat mRNAs corresponding to the receptors for PGD2, -E2, -F(2alpha), and -I(2) were expressed in human

93 PGD2-G, PGF2alpha-G and PGD2-EA, but not PGE2-EA or PGF2alpha-EA, also increased

94 glandin D2 synthase (Ptgds), and its product PGD2 each varied significantly among background strains

95 letion of alveolar macrophages abolished the PGD2-enhanced inflammatory response.

96 Amino-terminal deletions of PGD2 fusions with a free C terminus resulted in peroxiso

97 nflammation-related conditions, and proposes PGD2-G as a bioactive lipid with potential anti-inflamma

98 tro, as well as the 2-AG-induced increase in PGD2-G levels.

99 In addition, administration of PGD2-G reduces lipopolysaccharide-induced inflammation i

100 nflammatory prostaglandin D2-glycerol ester (PGD2-G).

101 ard PGE2-G, hABHD6 preferentially hydrolyzed PGD2-G, and human MAGL (hMAGL) robustly hydrolyzed all f

102 4)-prostaglandin J2-2-glycerol (15d-PGJ2-G), PGD2-G, PGE2-G, and PGF2 alpha-G.

103 PGD2-G, PGF2alpha-G and PGD2-EA, but not PGE2-EA or PGF2

104 ng order of activity: PGE2-G > PGF2alpha-G > PGD2-G; LYPLA2 hydrolyzed 1- but not 2-arachidonoylglyce

105 The early and late phases of PGD2 generation are mediated by prostaglandin synthase 1

106 12-epi-scalaradial, suppressed delayed-phase PGD2 generation at concentrations that did not affect im

107 Recombinant TSLP induced PGD2 generation by cultured human mast cells.

108 PGHS-2-dependent delayed-phase PGD2 generation elicited by IgE-dependent activation of

109 ein 1beta secretion, COX-2 upregulation, and PGD2 generation in mast cells.

110 arachidonic acid, its role in delayed-phase PGD2 generation is more complex and involves the activat

111 ytokine-primed, IgE-dependent, delayed-phase PGD2 generation occurred in BMMC from C57BL/6J mice, whi

112 Inhibiting PGD2 generation or signaling may be a useful mechanism o

113 yed phase of arachidonic acid release and of PGD2 generation was inhibited by heparin, which concomit

114 were stimulated with TSLP in vitro to assess PGD2 generation.

115 n the present study, we investigated whether PGD2 has the ability to stimulate Th2 cytokine productio

116 acid for early, PGS1-dependent synthesis of PGD2; (ii) secretory PLA2 does not play a role in the la

117 ole in the late, PGS2-dependent synthesis of PGD2; (iii) cytoplasmic PLA2 mediates the release of ara

118 unosuppressive axis by specifically blocking PGD2, IL-13 and NKp30 partially restores ILC2 and M-MDSC

119 LTE4 enhanced the effect of PGD2, IL-25, IL-33, and TSLP, resulting in increased pro

120 The effects of cysLTs, PGD2, IL-33, IL-25, TSLP, and IL-2 alone or in combinati

121 Synthesis and secretion of PGD2 in activated MMC-34 cells occurs in two stages, an

122 Proresolution functions were reported for PGD2 in colitis, but the role of its two receptors, D-ty

123 the enteric nervous system (ENS) to produce PGD2 in inflammatory conditions.

124 A significant role for PGD2 in mediating allergic responses has been suggested

125 determine the ability of the ENS to secrete PGD2 in proinflammatory conditions, Lipocalin-type prost

126 , the synergistic interaction of cysLTs with PGD2 in promoting TH2 cell activation is still poorly un

127 Instillation of PGD2 in the nose of sensitized mice together with a low

128 Thus, we hypothesized that decreases in PGD2 in the VLPO may contribute to the generalized arous

129 mplicated in the generation of both PGE2 and PGD2 in these cells by use of specific inhibitors and ef

130 e prostaglandins PGF2alpha and PGE2, but not PGD2, in rat cerebral cortical neurons in vitro.

131 Levels of racemic PGD2 increased 35-fold after treatment of rats with carb

132 PGD2 increased nonrapid eye movement sleep and induced s

133 Treatment of melanoma cell lines with PGD2 increased SOX9 expression and restored sensitivity

134 with niacin to abolish the prostaglandin D2-(PGD2)-induced flushing.

135 QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells.

136 rthermore, Gpr44-null mice were resistant to PGD2-induced inhibition of follicle neogenesis.

137 substance, but the neuroanatomical basis of PGD2-induced sleep is only partially understood.

138 ts of common pesticides on prostaglandin D2 (PGD2) inhibition in SC5 mouse Sertoli cells, evidence of

139 In all, these findings demonstrate that PGD2 inhibits hair follicle regeneration through the Gpr

140 to identify neurons activated by infusion of PGD2 into the subarachnoid space below the rostral basal

141 ur study demonstrates that mast cell-derived PGD2 is a major effector of type 2 immune responses driv

142 Prostaglandin D2 (PGD2) is an extensively studied sleep-promoting substanc

143 atory cells in response to prostaglandin D2 (PGD2), is hypothesized to play a role in Th2-mediated al

144 demonstrate that PGF2alpha, but not PGE2 or PGD2, is necessary but not sufficient for NMDA induction

145 We found that cytosolic PGD1 and PGD2 isozymes have heat-stable activity, while amyloplas

146 Stimulation by PGD2 led to phosphorylation of CREB, but had negligible

147 DS mRNA expression, and significantly higher PGD2 levels than healthy colonic mucosa.

148 l correlated such that the highest Ptgds and PGD2 levels were associated with the lowest amount of re

149 PGD2 levels were determined in a medium of primary cultu

150 PGD2 levels were significantly increased on primary cult

151 f NS398 and estradiol significantly elevated PGD2 levels.

152 nd LTE4 were observed in AERD (at 60 min for PGD2 , LTD4 , and LTE4 ) but not in MNSAID-UA or control

153 enge were analyzed for ECP, tryptase, PGE2 , PGD2 , LTD4 , and LTE4 .

154 Significant increases in PGD2 , LTD4 , and LTE4 were observed in AERD (at 60 min

155 aimed to comprehensively define the roles of PGD2, LTE4, and their combination in activating human TH

156 The effects of PGD2, LTE4, and their combination on human TH2 cell gene

157 For the first time, our results show that PGD2 markedly augments disease activity through its abil

158 These observations suggest that PGD2 may induce sleep via leptomeningeal PGD2 receptors

159 We investigated the expression of PGD2 metabolic pathway actors in Crohn's disease (CD) an

160 Expression of key actors involved in the PGD2 metabolic pathway and its receptors was analyzed us

161 Our results highlight the activation of the PGD2 metabolic pathway in Crohn's disease.

162 e of the importance of the prostaglandin D2 (PGD2) metabolic pathway in inflammatory bowel diseases.

163 Urinary levels of a stable PGD2 metabolite (uPGD-M) were 2-fold higher in patients

164 s concerning prostaglandin E2 (PGE2) and the PGD2 metabolite 15-deoxy-Delta(12,14)-PGJ2, and their di

165 ne was also collected, and quantification of PGD2 metabolite and leukotriene E4 levels was done by us

166 rently with significant increases in urinary PGD2 metabolite and leukotriene E4 levels.

167 These PGD2 metabolites activated the PPARgamma ligand-binding

168 ssion of PPARgamma-expressing tumor cells by PGD2 metabolites in the prostate microenvironment is lik

169 in D synthase (L-PGDS) and prostaglandin D2 (PGD2) metabolites produced by normal prostate stromal ce

170 achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored.

171 th or without OVA to determine the effect of PGD2 on nasal responsiveness.

172 the peptide coding sequence to the Pgd1 and Pgd2 open reading frames (ORFs).

173 mmunization and then was boosted with either pgD2 or MVA-gD2.

174 ntrast, the time course of prostaglandin D2 (PGD2) or 9 alpha, 11 beta PGF2 (11 beta PGF2) formation

175 1 beta-PGF2 alpha but was unchanged by 10 nM PGD2, PGE2, PGF1 alpha, carbaprostacyclin, U-46619, or 1

176 clone catalyzed the transport of PGE1, PGE2, PGD2, PGF2alpha, and, to a lesser degree, TXB2.

177 misoprostol but not with 10(-6) M PGF2alpha, PGD2, PGI2, or butaprost, suggesting a principal depende

178 Prostaglandin D2 (PGD2 ) plays an important role in allergic inflammation.

179 ons found at sites of allergic inflammation, PGD2 preferentially elicited the production of IL-4, IL-

180 These data suggest that PGD2 preferentially up-regulates proinflammatory cytokin

181 y represented approximately 30% of the total PGD2 present in urine.

182 n-2 and interferon-gamma than did those from pgD2-primed mice, indicating that a prime-boost immuniza

183 h MVA-gD2 and boosted with either MVA-gD2 or pgD2 produced higher levels of interleukin-2 and interfe

184 PGD2, produced by mast cells, has been detected in high

185 also able to inhibit both the early phase of PGD2 production and the secretion of PLA2 activity by ac

186 , (ii) group V PLA2 mediates early mast cell PGD2 production and transcellular PGE2 production in mur

187 Reducing PGD2 production by inhibiting COX-2 or PGD2 synthase imp

188 PLA2 activation and is necessary for optimal PGD2 production by the secretory PLA2/PGS1-dependent ear

189 PGE2 synthesis, at the same time decreasing PGD2 production in a reciprocal fashion.

190 Gpr44 receptor and imply that inhibition of PGD2 production or Gpr44 signaling will promote skin reg

191 PGE2 production was suppressed by ibuprofen, PGD2 production was not.

192 y thromboxane B2, prostaglandin (PG) E2, and PGD2 production, in addition to lysophospholipid acyltra

193 15-epi-LXA4 or MaR1 down-regulated PGE2 and PGD2 production.

194 l, pyrimethanil, and tebuconazole suppressed PGD2 production.

195 he ENS, ECG and neurons, could contribute to PGD2 production.

196 PGD2 promotes the growth of retinal capillary pericytes

197 Two PGD2 receptors have been identified: PGD2 receptor 1 (DP1, also called DP) and PGD2 receptor

198 d: PGD2 receptor 1 (DP1, also called DP) and PGD2 receptor 2 (DP2, sometimes termed CRTH2).

199 A NKp46+ subset of ILC3 expresses the PGD2 receptor CRTH2 and is the source of the increased I

200 f PGD2 decreased WIHN in wild-type mice, and PGD2 receptor Gpr44-null mice showed increased WIHN comp

201 d pulmonary inflammation, activation of each PGD2 receptor resulted in aggravated airway neutrophilia

202 The PGD2 receptor, CRTH2, is expressed on basophils, eosinop

203 ene acid 1-E to give 2, a prostaglandin D2 (PGD2) receptor antagonist.

204 that mice deficient in the prostaglandin D2 (PGD2) receptor CRTH2 and mice with CRTH2 deficiency only

205 Two PGD2 receptors have been identified: PGD2 receptor 1 (DP

206 Activation of PGD2 receptors on human macrophages enhanced the migrato

207 We investigated the role of PGD2 receptors on primary human macrophages, as well as

208 hat PGD2 may induce sleep via leptomeningeal PGD2 receptors with subsequent activation of the VLPO.

209 receptors caused a marked increase in AA and PGD2 release after stimulation of BMMC, implicating sPLA

210 ast cells with measurements of Ca2+ flux and PGD2 release.

211 an mast cells directly through Ca2+ flux and PGD2 release.

212 ate in the cytosol and chloroplasts, whereas PGD2 remains in the cytosol.

213 Further, VIP induced PGD2 secretion from eosinophils.

214 Changes in PGD2 secretion in juvenile mouse Sertoli cells (SC5 cell

215 or the COX inhibitors alone had an effect on PGD2 serum levels, co-administration of NS398 and estrad

216 ht arise from simultaneous interference with PGD2 signaling and androgen action.

217 Furthermore, PGD2 signaling via CRTH2 was found to diminish the suppr

218 n the small intestine, which is dependent on PGD2 signaling.

219 PGE2 and PGD2 specifically reduced the proportion of macrophages

220 9 behaved as an insurmountable antagonist of PGD2-stimulated [(35)S]-GTPgammaS activation, and its ef

221 All CRTh2 antagonists tested inhibited PGD2-stimulated human eosinophil shape change, but impor

222 angerhans cells to produce prostaglandin D2 (PGD2), stimulating vascular DP1 receptors to cause vasod

223 ast cells sorted from nasal polyps expressed PGD2 synthase (hematopoietic PGD2 synthase) mRNA at high

224 ed strongly with mRNA encoding hematopoietic PGD2 synthase (r = .75), the mast cell-specific marker c

225 ucing PGD2 production by inhibiting COX-2 or PGD2 synthase improves RSV clearance kinetics through DC

226 olyps expressed PGD2 synthase (hematopoietic PGD2 synthase) mRNA at higher levels than did eosinophil

227 2 and PGE2 synthase, between COX-1/COX-2 and PGD2 synthase, and also between COX-1 and thromboxane A2

228 ways of transgenic mice overexpressing human PGD2 synthase, and PGD2 can enhance Th2 cytokine product

229 paper that lipocalin-type prostaglandin D2 (PGD2) synthase (L-PGDS) interacts intracellularly with t

230 Surprisingly, PGD2 synthesis by L-PGDS is promoted by coexpression of

231 Early phase PGD2 synthesis in activated mast cells also requires the

232 e Pla2 g2a gene both demonstrate early phase PGD2 synthesis.

233 ate most of the pesticides shown to suppress PGD2 synthesis.

234 varied than previously thought can suppress PGD2 synthesis.

235 ic PGD synthase, the rate-limiting enzyme of PGD2 synthesis.

236 Prostaglandin D2 (PGD2) synthesis in activated mast cells occurs in two ph

237 European Union to suppress prostaglandin D2 (PGD2) synthesis.

238 ucted to determine the site of action in the PGD2 synthetic pathway.

239 ze also has two cytosolic isozymes, PGD1 and PGD2, that are not required for kernel development.

240 (PG) release from RASMCs, including that of PGD2, the precursor of the putative endogenous PPARgamma

241 gest that TNFalpha induced a switch from the PGD2 to PGE2 synthesis pathway by regulating PGE2 syntha

242 the binding mode for the endogenous agonist (PGD2) to DP.

243 Repeated selfing of pgd2 transfer (T-)DNA alleles yielded no homozygous muta

244 PGD2 treatment induced c-fos mRNA, stimulated pericyte g

245 We report here that an inflammatory PG, PGD2, via its receptor, mediates the activation of NF-ka

246 PGD2 was administered with or without OVA to determine t

247 The effect of PGD2 was mimicked by the selective CRTH2 agonist 13,14-d

248 of the natural prostaglandins PGF2alpha and PGD2 was not enhanced by the mutations.

249 PGE2 and PGD2 were elevated early and late, respectively, during

250 rawal latencies and serum levels of PGE2 and PGD2 were measured in rats treated with estradiol (0, 10

251 P receptor agonists U-46,619, PGF2alpha, and PGD2 were more potent than PGE2.

252 Racemic PGE2 and PGD2 were present esterified in phospholipids derived fr

253 the groups, but levels of LTD4 , LTE4 , and PGD2 were significantly higher in AERD group.

254 In addition, racemic PGs, particularly PGD2, were present unesterified in urine from normal ani

255 thermore, we also show how prostaglandin D2 (PGD2), which is upregulated in balding scalp, differenti

256 Prostaglandin D(2) (PGD2), which reduces DC migration through the elevation

257 inhibited Th2 cytokine production induced by PGD2, while the selective thromboxane-like prostanoid re

258 tosolic and/or plastidic enzyme plus whether PGD2 with a peroxisomal targeting motif also might targe